Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2013 Nov-Dec;12(6):375-7.
doi: 10.1177/2325957413495567. Epub 2013 Jul 23.

Interactions between alcohol and the HIV entry inhibitor Maraviroc

Valerie A Gruber  1 , Petrie M Rainey, Paula J Lum, George W Beatty, Francesca T Aweeka, Elinore F McCance-Katz
Affiliations
Randomized Controlled Trial

Interactions between alcohol and the HIV entry inhibitor Maraviroc

Valerie A Gruber et al. J Int Assoc Provid AIDS Care. 2013 Nov-Dec.

Abstract

Background: Alcohol use is common among people with HIV, and beliefs about alcohol interactions with medications predict decreased medication adherence, risking drug-resistant mutations. Maraviroc is an HIV entry inhibitor approved for treatment of both drug-sensitive and drug-resistant HIV strains. The present study evaluated the effects of alcohol on maraviroc pharmacokinetics and the effects of maraviroc on alcohol pharmacokinetics.

Methods: Ten healthy adults completed alcohol (1 g/kg) and placebo alcohol pharmacokinetics sessions before and after 7 days of maraviroc administration.

Results: Alcohol concentrations increased 12% following maraviroc. Maraviroc pharmacokinetics were unaffected by alcohol.

Conclusions: Maraviroc treatment should not be interrupted if alcohol is consumed.

Keywords: HIV/AIDS; alcohol; drug interactions; maraviroc.

PubMed Disclaimer

References

    1. Chander G, Lau B, Moore RD. Hazardous alcohol use: a risk factor for non-adherence and lack of suppression in HIV infection. J Acquir Immune Defic Syndr. 2006;43:411–417. - PMC - PubMed
    1. Kalichman SC, Grebler T, Amaral CM, et al. Intentional non-adherence to medications among HIV positive alcohol drinkers: prospective study of interactive toxicity beliefs. J Gen Intern Med. 2013;28(3):399–405. - PMC - PubMed
    1. Bangsberg DR. Preventing HIV antiretroviral resistance through better monitoring of treatment adherence. J Infect Dis. 2008;197:S272–S278. - PubMed
    1. Lieberman-Blum SS, Fung HB, Bandres JC. Maraviroc: a CCR5-receptor antagonist for the treatment of HIV-1 infection. Clin Ther. 2008;30(7):1228–1250. - PubMed
    1. Hyland R, Dickins M, Collins C, Jones H, Jones B. Maraviroc: in vitro assessment of drug-drug interaction potential. Br J Clin Pharmacol. 2008;66(4):498–507. - PMC - PubMed

Publication types

MeSH terms